Demand for AI-powered tools to accelerate drug discovery and research has risen across pharmaceutical companies, academic institutions and biotech firms [File] | Photo Credit: REUTERS OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and scientific research capabilities, as the startup deepens its push into the life sciences field. The GPT-Rosalind, named after 20th-century British scientist Rosalind Franklin, is designed to support research across biochemistry, drug discovery and translational medicine. Published – April 17, 2026 10:28 am IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Filmmaker Fazil Razak on ‘Moham’ selected for Moscow International Film Festival 2026 Observance of death anniversary of Biju Patnaik; a tussle to appropriate legacy in Odisha